In recognition of Hispanic Heritage Month, our team came together to celebrate, learn, and honor Hispanic and Latino communities, blending cultural celebrations and storytelling with scientific dialogue. Through a thoughtful symposium, we traced the origins of Hispanic Heritage Month, highlighting the importance of data-driven insights and the role culture can play in advancing patient care. The program concluded with a powerful patient story demonstrating how intentionality improves outcomes. Events like these embody our values of Inclusiveness & Fairness and Tireless Commitment to Patients and remind us that delivering Transformative Science to all patients requires us to be Exceptional Together.
Revolution Medicines
Biotechnology Research
Redwood City, California 33,171 followers
Translating Frontier Oncology Targets to Outsmart Cancer
About us
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
- Website
-
http://www.revmed.com
External link for Revolution Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
Get directions
700 Saginaw Dr.,
Redwood City, California 94063, US
Employees at Revolution Medicines
Updates
-
We’re pleased to announce that Alan Sandler, M.D. has joined Revolution Medicines as our new chief development officer. Alan brings deep oncology expertise and experience with a proven track record in both industry and academia, reflecting his deep commitment to advancing cancer research and creating new treatment options for patients. Read more: https://lnkd.in/gYXJqtCe
-
-
We’re excited to welcome Gerwin Winter as Senior Vice President, Head of Europe, to the Revolution Medicines team. Based in Basel, Switzerland, Gerwin will lead our cross-functional European Region team and collaborate globally as we grow in pursuit of our mission to serve patients with RAS mutant cancer. Gerwin brings more than 20 years of oncology leadership spanning commercial, operational, and management roles. His expertise will be invaluable as we expand our global presence and strive to deliver innovative therapies to patients worldwide.
-
-
Today, we’re excited to share three compelling new clinical datasets for our lead RAS(ON) inhibitor in metastatic pancreatic ductal adenocarcinoma (PDAC): • Long-term follow-up data for RAS(ON) inhibitor monotherapy in second line metastatic PDAC • Initial clinical results for RAS(ON) inhibitor monotherapy in first line metastatic PDAC. • Initial clinical results for RAS(ON) inhibitor therapy plus chemotherapy in first line metastatic PDAC. These datasets underscore the potential of innovative targeted therapies for patients with RAS mutant PDAC and support our plans to initiate a global, randomized Phase 3 trial in first line metastatic PDAC later this year. Learn more, including information about our Investor Webcast today at 2 pm PT: https://lnkd.in/gKcZNw87 #PancreaticCancer #ClinicalTrials #RAS #Oncology
-
We join the community in mourning the loss of Bonnie J. Addario, whose vision and advocacy transformed the landscape for lung cancer patients and families. Her legacy as a leader, champion, and unifier will continue to inspire those of us working to improve outcomes in lung cancer.
With heavy hearts, we share the passing of our beloved co-founder and leader of GO2 for Lung Cancer, founder of the Bonnie J. Addario Lung Cancer Foundation, and founder of Addario Lung Cancer Medical Institute, Bonnie J. Addario. Bonnie was an extraordinary woman whose vision, strength, and generosity transformed the lung cancer space forever. Following her own diagnosis, she turned adversity into action—channeling her experience into a movement that put patients first. From patient to powerhouse, Bonnie became a fierce and tireless advocate, giving voice and hope to countless individuals and families impacted by lung cancer. She united survivors, caregivers, health care providers, researchers, industry leaders, and policymakers to confront this disease with compassion, innovation, and urgency. While her loss is deeply felt, Bonnie’s legacy lives on—in the lives she touched, the progress she inspired, and the unwavering belief she held: that every person affected by lung cancer matters. We honor her by continuing the mission she so passionately led—with courage, love, and hope.
-
-
Today we reported our Q2 2025 financial results and shared key updates as we advance our bold vision for patients with RAS-addicted cancers. Recent highlights include: • Strong execution of two ongoing global Phase 3 trials in PDAC and NSCLC • FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors • Execution of transformative flexible funding agreement to support our global development and commercialization strategy • Progress on earlier-stage pipeline programs and strategic collaborations Read the full release: https://lnkd.in/gp4me9Tw
-
-
Our research, now published in Science Magazine, highlights a breakthrough approach to targeting KRAS G12D, the most common oncogenic RAS mutation driving human cancers, which led to the discovery of our investigational RAS(ON) G12D-selective inhibitor. Read more about this advancement in our release: https://lnkd.in/gUCuRbhd #PrecisionOncology #CancerResearch #KRAS #PancreaticCancer #RASinhibitors
-
-
The FDA has granted Breakthrough Therapy Designation to our investigational RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor. This marks the second Breakthrough Therapy Designation for Revolution Medicines’ pipeline, following the designation of our RAS (ON) multi-selective inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with KRAS G12 mutations. We are grateful for the dedication of our team, clinical collaborators, and—most importantly—the patients and families who make this progress possible. Learn more: https://lnkd.in/gjR7k_YD
-